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Abstract 
Cancer has long been known as a dreadful disease characterized by uncontrolled proliferation of 
tumor cells. Despite many breakthroughs in biotechnological fields and the discovery of various potent 
anticancer agents the need in chemotherapy is still unmet. Cancer develops by various mechanisms and 
the most common mechanism involves mutations in genes. Topoisomerase II is critical for DNA 
replication, transcription and chromosome segregation and is a well validated target of anti-neoplastic 
drugs including the anthracyclines and epipodophyllotoxins. However, these drugs are limited by 
common tumor resistance mechanisms and side-effect profiles. Novel topoisomerase IT-targeting agents 
may benefit patients who prove resistant to currently available topoisomerase IT-targeting drugs or 
encounter unacceptable toxicities. Quinolones form an interesting group of molecules that have been 
intriguing the scientific world in recent years. The last few generations have seen the development of 
quinolone based drugs. They are well known for their activity against a broad spectrum of bacteria. Drugs 
such as ciprofloxacin, gatifloxacin, levofloxacin have stormed the clinical world within a short span of 
time. The last few years have witnessed the development of numerous novel tricyclics and tetracyclic 
quinolones that target mammalian topoisomerase I and II. The starting point of this research was a 
thiazoloquinolone which was patented by Kyorin!K.yowa-Hallo. This compound exhibited a promising 
cytotoxic profile in different animal models. 
Using Alchemy-3™, the optimum configuration of the patented compound was determined and 
based on this a linear tricyclic quinolone scaffold was designed and used in our research as a fundamental 
pharmacophore to synthesize novel molecules with antineoplastic profiles. 
This thesis is arranged into four chapters. The first chapter gives a brief history of cancer, 
quinolones and some of the classic synthetic reactions in the synthesis of 4-quinolones. Chapter 2 
provides a review of anticancer quinolones structure-activity relationships and outlines the potential 
medical uses of quinolones apart from their classic use as antibacterial agents. Chapter 3 describes various 
aspects of synthetic procedures involved in the preparation of novel quinolone compounds and biological 
11 
evaluation methods. Finally, chapter 4 concludes this thesis with a discussion of a possible future work. 
Thus, a number of thieno[2,3-b ]quinolones and the corresponding furoquinolones have been synthesized 
adapting conventional methods. The cytotoxicity screening of the target compounds was performed 
against HeLa and Kb cell lines. Unfortunately, the compounds have not shown reasonable activity. 
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Chapter 1: Introduction 
History 
One of the major causes of mortality in humans on earth is cancer. In 2007, approximately 29.6% 
of deaths were caused by cancer making cancer as the leading cause of mortality (Figure 1.1). It is 
estimated that 186,400 people will be affected by cancer and 75,700 deaths will occur in Canada in 
20 12 [ 1]. Generations of research have accumulated vast amount of data with no success in cure for 
this dreadful disease. Rapid advances in bio-medical techniques and investing considerable time into 
this domain have led to considerable progress against cancer in recent years. 
Proport•on of deaths due to cancer and other causes, Canada, 2007 
Chrll'nlc i ii'Wft 
t•s.poootcty di~ .. ~·•~ . 
U '> 
Cancer, 
29.6%. 
Ols•ans ol • twort 
~~ 
M•~~ed ro t: t•t<l 9 eous•·s or 4'<N11'1. 
C anada. 2007. S~a -sb~s Ca ad\a,. 
Figure 1.1. Piechart of Cancer Statistics 
Although the idea of "chemotherapy", by Paul Ehlrich , came up in the early 19th century, it 
was not until World War II that this therapeutic approach began to be utilized in the treatment of cancer. 
The mustard gas explosions at Bari Harbour and its aftermath led researchers to develop numerous less 
toxic and more tolerable derivatives for the treatment of leukemias and lymphomas [2]. After a few years 
of research in this area it turned out that apart from alkylating agents (e.g.,- nitrogen mustards and its 
2 
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derivatives), folic acid, an integral part of cell development, was found to have inhibitory effect on 
proliferation of leukemic cells in childhood [3]. With this development, efforts have been intensified in 
this field and with the progression of screening and testing models a vast number of promising drugs with 
wide spectrum anti-tumour activity have thronged the therapeutic world. Archetypically, anti-cancer drugs 
are categorized as chemotherapeutic, hormonal therapeutic and immunotherapeutic agents (Table 1.1 ). 
Drugs under these categories are classified according to their chemical structure and mechanism of action 
[4]. Chemotherapeutic agents include: 1) Alkylating agents, which act by cross-linking DNA and thus 
blocking cell division; 2) Antimetabolites, which act by inhibiting the synthesis of precursor molecules 
essential for cell division; 3) Antimitotics, which act by hindering chromosomal arrangement required for 
cell division; 4) Antibiotics, possessing any of the above mentioned functions; 5) Topoisomerase 
inhibitors; and 6) Others, which expanded so much that this classification is no longer useful. 
Hormonal therapy includes all the steroid drugs (anti-estrogens, anti-androgens, anti-aromatase 
agents, LH-RH analogs, etc.). Immunotherapy includes interferons, interleukins and vaccines. 
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Table 1.1. Classical classification of anticancer drugs 
Chemotherapy 
Hormonal therapy Steroids 
Immunotherapy 
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Alkylating agents 
Antimetabolites 
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Mitosis inhibitors 
Antibiotics 
Topoisomerases inhibitors 
Others 
Anti-estrogens 
Anti-androgens 
LH- RH analogs 
Anti-aromatase agents 
Interferon 
Interleukin 2 
Vaccines 
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The beauty of chemotherapeutic agents is their target specificity and specific modes of action. 
One of the prominent members of chemotherapeutic agents is "DNA Topoisomerase Inhibitors and 
Poisons". Generally, these molecules interact with either Topoisomerase-1 or -II at their catalytic or 
DNA-binding domains, stabilizing a cleavable ternary DNA-enzyme complex that does not permit the 
resealing of nicked DNA [5,6] . Recently, 4-oxo-1,4-dihydroquinolone-3-carboxylic acids (quinolones) 
that interact with human as well as bacterial topoisomerases have attracted medicinal chemists' attention 
as potential anticancer agents. 
1.2. Molecular Targets of Anticancer Quinolones 
Bicyclic core structured quinolones have long been known for their antibacterial activity [7, 8]. 
The mode of action by which quinolones act on cancer cells was unknown initially. Decades of research 
into antibacterial quinolones has generated some vital aspects of their cellular targets and modes of action. 
Studies have shown that DNA gyrase (Gyr) and DNA topoisomerase IV (Topo 4) are the primary targets 
through which they exert their antibacterial activity in prokaryotes [9]. DNA topoisomerases are vital to 
maintaining the helical structure of DNA and are present in all prokaryotic and eukaryotic organisms .. 
Due to the intertwined nature of its double helical structure, during the replication process DNA becomes 
distorted ahead of the replication fork. The distortion of DNA develops tension within the coil that if left 
unabated it causesa halt in replication. DNA topoisomerases bind either to single-stranded or double-
stranded DNA[10]. Depending upon the nature of binding either tosingle or double strand DNA, 
topoisomerases are divided into two types : topoisomerase I and topoisomerase II. The enzymes that 
cleave only one strand of DNA are confined under type I and those enzymes that cleave two strands of the 
DNA are defined as type II. For many years, following the discovery oftopoisomerase II, it was believed 
that there is only a single isozyme existed and as of this writing, it is still the same script for lower 
eukaryotes, such as yeast [11-14] and Drosophila [15]. But further studies have later demonstrated the 
5 
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existence of a second isoform of the enzyme in mammalian cells [ 16, 17]. Table 1.2 [ 1 0] presents an 
overview of the classification ofTopoisomerases. 
Table 1.2. Classification ofDNA Topoisomerases [10] 
Topoisomerase• Predominantly 
subfamily studied members 
Bacterial DNA 
topoisomerases I & III 
(E. coli) 
Yeast DNA 
lA topoisomerase III (S. 
cerevisiae) 
Mammalian DNA 
topoisomerase Ilia & 
~ 
Eukaryotic DNA 
m topoisomerase I 
(human) 
Poxvirus DNA 
topoisomerase 
(vaccinia) 
Hyperthermophilic 
eubacterial DNA 
topoisomerase V 
(Mathanopyris 
kandleri)" 
6 
Subunit 
Structure 
Monomer 
Monomer 
Monomer 
Monomer 
Monomer 
Monomer 
Size (S) 
(aa)b 
865 and 653 
656 
1001 and 862 
765 
314 
ITA 
liB 
Eubacterial DNA gyrase 
(E. coli) 
Eubacterial DNA 
topoisomerase IV (E. 
coli) 
Yeast DNA 
topoisomerase II (S. 
cerevisiae) 
Mammalian DNA 
topoisomerase IIa & 
II~ (human) 
Archaei DNA 
topoisomerase VI 
(Sulfolobus shibatae) 
C2E2 heterotetramer 
Homodimer 
Homodimer 
A2B2 heterotetramer 
Chapter 1: Introduction 
Gyr A (875), Gyr B 
(804) 
Pare (752), ParE 
(630) 
1428 
1531 & 1626 
A(389), B(530) 
"The source of the most extensively studied family member is given in parenthesis. The top portion ofthe table 
lists the type I topoisomerases; the bottom portion the type II enzymes. 
bThe subunit sizes are those corresponding to the most extensively studied family member. 
00nly known representative at present. Probably present in other hyperthermophilic eubacteria. 
Thus two isoforms a and ~' which can be discerned by their polypeptide molecular masses, have 
been uncovered. Since the discovery of the structure of DNA, the next breakthrough in biology came in 
the form of discovery of DNA topoisomerases by James Wang [18]. From there, intensive research has 
been done into determining the structure of DNA topoisomerases. 
During the 1970s and 1980s extensive studies were done on the cellular pharmacology of DNA 
crosss-linking agents such as nitrogen mustards and other agents. It is during this time that 
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topoisomerases were discovered to be the targets of anthracyclines and several other classes of anticancer 
agents. Thus, one of the long standing beliefs that quinolones act on bacterial topoisomerases has come 
to an end with the appearance of the first report on the in vitro interference of some antibacterial 
quinolones with the eukaryotic DNA replication [19] . With this study organized investigations have been 
carried out on quinolone selectivity between bacterial and mammalian type II topoisomerases [20-22]. 
1.2.1. Structure of Human Topoisomerase I, IIa & rrp 
1.2.1.1. Structure ofTopoisomerase I (topo I) 
Human topo I, the prototype of the type IB topoisomerase family, catalyzes transient changes in 
the superhelical state of double stranded DNA by breaking one strand of the DNA to allow gyration 
of one region of the double helical structure relative to another region [23]. 
Human Top I is a monomeric 765 amino acid (91 -kDa) enzyme [24], based on the limited proteolysis 
studies of human topo I and the crystallographic structure determination of an inactive fragment of the 
yeast enzyme [25,26]. 
The protein can be divided into four major regions: the NH2 terminal, core, linker, and COOH-
terminal domains. The NH2-terminal region of the enzyme is highly charged with few amino acids, and is 
poorly conserved [26]. The COOH-terminal domain, comprising residues ~ 713 to 765 contains the 
essential catalytic Tyr723, and the poorly conserved and positively charged linker region that connects the 
C-terminal domain to the isolated core domain to reconstitute near full enzyme activity (Figure 1.2). 
8 
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Core Subdomain 1 
I Cor• Subdomain nl 
Figure 1.2. The structure of reconstituted human topoisomerase I. (A) Viewed perpendicular to the pore. Core 
subdomains ~ II, and III are shown in yellow, blue, and red, respectively, and the COOH-terminal domain is shown in green. The enzyme consists 
of a "cap" consisting of core subdomains I and II (with the extended nose-cone helices facing to the right), and the closely associated complex of 
core subdomain III and the COOH-terminal domain at the bottom. (B) A view of the enzyme down the pore, rotated 90° about the vertical axis 
relative to (A), and with the domains colored as indicated above. The central pore of the molecule varies from 15 to 20 A in diameter and 
provides an extensive, highly positively charged binding region for the substrate DNA. The cap of the molecule and core subdomain III contact 
one another at two lips (residues 367 to 369 of subdomain I and residues 497 to 499 of subdomain III), as shown on the right central part of this 
figure. Adopted from M.R. Redinbo et al., (1998). Science, 279 (5356), 1504-1513 [Ref. 25) 
Based on crystallographic studies, topo I is a bi-lobed protein that clamps completely around 
duplex DNA through protein-DNA phosphate interactions [25]. The core domain of the protein can be 
further divided into two subdomains I, II, III. Subdomain I consists of residues 215 to 232 and 320 to 433 
and is made up of two a helices and nine ~ strands and subdomain II is made up of residues 233 to 319 
and is composed of five a helices and two ~ strands. Lobe 1, which consists of subdomains I and II fold 
firmly together and form the top half or "cap" of the enzyme. The second lobe (core subdomain III, 
which runs from residue 434 to 635 and is a disordered arrangement of 10 a helices and 3 ~ strands, the 
linker, and the C-terminal domain) sits below the DNA and contains the catalytic residues implicated in 
the strand cleavage and religation reactions (Figure 1.2. A ). Subdomains I and III interact via two short 
9 
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"lips" opposite from these helices. Because, to date there is no free enzyme crystal structure available, all 
the examinations are done on the available crystal structures of human topo I bound DNA. Thus, little is 
known about the conformation of the DNA-free enzyme or the nature of the conformational changes that 
accompany the DNA binding. But crystallographic examination of the enzyme bound DNA reveals that, 
in order for the DNA to dissociate from the enzyme, subdomain I and subdomain II must move apart from 
Subdomain III and the C-terminal domain. [25, 26]. 
1.2.1.2. Structure ofTopoisomerase II (topo II) 
As described previously, topo II alters DNA topology by a double-stranded DNA passage 
mechanism. To date there is no crystallographic data available for either of these full length isozymes. 
Human cells express two distinct type II topoisomerase isozymes, designated topoisomerase IIa (topo IIa, 
170 kDa form) and topoisomerase II~ (topo II~, 180 kDa form). The latter isozyme has been discovered 
in 1987 [27]. These proteins share the same catalytic cycle. Alignment of the sequences of the type IIa 
subfamily are based on their homology with E. coli DNA gyrase [28], and is divided into three distinct 
domains (Figure 1.3). [ 10, 29-33]. TheN-terminal half of the GyrB and the corresponding human DNA 
topoisomerases contain the ATPase domain. The central domain of the enzyme, which extends up to 
approximately amino acid 1200, is homologous to the A subunit of DNA gyrase and contains the active 
site tyrosine residue [10, 31, 33-35] . The C-terminal domain is highly variable and does not correspond 
with the -COOH domain of the bacterial DNA gyrase [31, 34 ], however, is believed to play a vital role in 
the physiological regulation of the enzyme [36]. In the absence ofC-terminal domain from the homology 
comparisons, the sequence identity of the amino acids rises from ~70% to 80% [37-40]. 
10 
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DNA Binding/Cleavage Domain 
ATPase B' A' C·terminal tail 
Human topo Ila 
678 1171 1531 
Human topo 1113 
694 1183 1626 
E. coli D:t\ A 
gyrasc J%~>05 875 
I 
sso 719 
Figure 1.3. Sequence comparisons among type II topoisomerases. 
1.2.2. Catalytic Cycle ofTopoisomerase IT 
Due to its role, which maintains the integrity of the mammalian cell (in general) and its 
involvement in progression of cancer, it is essential to understand the function of the topo II enzyme and 
its biological properties. Enzymological characteristics and physiological regulation probably have a 
direct correlation with the cellular roles of topo II a and IIB. During normal cell growth cycles the 
concentrations ofthe topo IIa and IIB remain constant [41]. However, the concentration ofthe a isozyme 
is considered to increase by 2-3-fold during Gi M phase [ 42-46] and is higher in rapidly profilerating cells 
than it is in quiescent populations [ 41-48]. Intensive research over the past decade on the topo II enzyme 
has resulted in the postulation of schematic steps on the mechanism of double-stranded DNA passage 
reaction [ 4 7-51]. Discrete steps of the topo II catalytic cycle are shown in Figure 1.4, which shows one 
cycle of enzyme activity and is briefly described as follows: 
1.2.2.1. Binding 
Initiation of the catalytic cycle starts with the binding of topo II to its DNA substrate. This stage 
does not require a cofactor [52, 53]. Nucleotide sequence and the conformation of the double helix 
structure govern this interaction. The ability of the enzyme to distinguish the conformation of the DNA 
11 
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overlies on its recognition of points of helix-helix juxtaposition [54, 55]. This stage of the interaction 
occurs at specific nucleotide sequences that defines the enzyme-mediated DNA cleavage [55, 56]. The 
mechanism by which topo II locates DNA nucleic acid sequences in unknown. 
1.2.2.2. Cleavage/Religation 
In the presence of a divalent cation, topo II establishes anequilibrium between DNA 
cleavage/religation [57, 58, 59] . During the cleavage reaction, the enzyme generates co-ordinated breaks 
on opposite strands of DNA and leaves a four-base 5'-overhang on each nucleic acid strand [58, 59]. 
During this stage the enzyme maintains the structural integrity of the DNA substrate by forming a 
"cleavage complex" covalent bonds between 5' -phosphate termini of the DNA and active tyrosyl residue 
(04-phosphotyrosyllinkage) [34, 59, 60]. 
1.2.2.3. Passage of DNA Strand 
Upon binding of its ATP cofactor, topo II undergoes a topological change [60, 61]. Simultaneous 
to this change, the intact DNA helix bypasses via the transient double-stranded break [51]. This forms 
ATP-bound cleavage complex, which led to a proposal that topo II acts as a ' protein clamp' prior to 
recycling [62,63]. The triphosphate portion of the ATP also is elemental in the induction of strand passage 
[64]. 
1.2.2.4. Post ATP-DNA Cleavage/Religation 
Following the portal episode, the enzyme for the second time reaches a DNA cleavage/relegation 
equilibrium [51]. The cleavage complex formed in the presence of ATP is 2-4 times more sturdy than the 
one formed prior to ATP binding [51]. (Figure 1.4). 
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Figure 1.4. Type II Topoisomerase Mechanism [60] 
1.2.2.5. Hydrolysis 
Ensuing the post-DNA cleavage/religation event, topo II hydrolyzes its Adenosine Tri-phosphate 
(ATP) cofactor to adenosine di-phosphate(ADP) and orthophosphate [5 1 ,64] . 
1.2.2.6. Enzyme turnover 
Finally, cycle 2 is triggered following the ATP hydrolysis, topological state of the enzyme is 
regenerated to the pre-strand passage stage conformation. Subsequently, the Top II enzyme discharges the 
resultant DNA product, spontaneously kicks starting a new cycle [51]. 
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1.2.3. Topoisomerase II As Biological Toxin 
DNA topoisomerases - "Magicians of the DNA world" as referred by James C. Wang- possess 
special enzymatic capacity to solve various topological problems at various stages of the cell cycle. The 
human genome is comprised of -4 billion base pairs of DNA that are cordoned off in 46 chromosomes. 
Each adult human body has 6.5 feet of DNA stranded in each cell. If all the strands in human body could 
be strung together, it would stretch 70 times of the distance between the earth and the sun [65]. Due to its 
tremendous length, DNA is present in a highly conserved state which in its role has to survive various 
stages of cell cycle: replication, transcription and recombination to enhance the growth of a cell. 
Topoisomerase II has its own niche in solving various topological problems of the DNA and thus is 
essential for survival. The topo II catalytic reaction which generates double-stranded DNA breaks are 
normally reversible [35, 66]. As mentioned before, the concentrations of the topo II enzymes are in higher 
orders of magnitude in cancer cells. If conditions facilitate the increase in lifetime of the topo II-DNA 
cleavage complex, the probability of occurrence of numerous mutagenic events such as insertions, 
deletions, and abnormal recombinations are inexorable [31 , 66]. Further, the action of polymerase or 
helicases to reverse the enzyme-DNA cleavage complex, jeopardizes the normal cell cycle [67, 68]. The 
indulgence of these proteins converts transient topo II-DNA cleavage complexes to permanent cleavage 
complexes, which can no longer be sutured. These disrupted cleavage complexes would be the substrates 
for mutational repair pathways, involving insertions, deletions, production of chromosomal 
translocations, etc. [69, 71]. The presence of these DNA breaks in high numbers initiates a series of 
apoptotic events that ultimately terminates the cell [72]. 
DNA topoisomerase II is also the target of several antineoplastic agents. Despite the structural 
diversity among topo IT-targeted agents, many drugs share a common ground, the ability to bind to the 
DNA-topo II complex. Topo II inhibition has proved to be a highly successful approach, especially when 
using doxorubicin and etoposide, for therapeutic intervention. Most of the topoisomerase inhibitors show 
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selectivity against either topo I or topo II, only a few compounds act on both these enzymes. However, 
since the interest of this dissertation lies on a specific class of drugs acting as topo II poisons, an overview 
of the drugs targeting topo II would assist a reader to better understand the concept. Table 1.3 [73] shows 
few drugs which act as topo II poisons and are still under investigation. 
Table 1.3. Investigational Agents which Inhibit Topoisomerase II 
Amonifide Elliptinium Nitroimidazole 
Amsacrine Epirubicin Saintopine 
Anthrapyrazoles Ethidium Bromide Streptonigrin 
AzaiQD Genistein Suramin 
Azatoxin lntoplicine Whitangulatin 
Bis (2,6-dioxopiperazine) Makaluvamines 
Bulgarein Merbarone 
Distamycin Menogaril 
Ditercalinium N aphthoquinones 
15 
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COOH 
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Figure 1.5. Drugs that Target Topoisomerase II [ 41] 
Structures of some of the most promising topo II poisons to date are depicted in Figure 1.5. 
Especially, etoposide when administered in combination with other agents is the most effective compound 
against germ line cancers, non-Hodgkins lymphoma and several leukemias [74,75] . The quinolone 
derivative, CP-115,953 is the most widely investigated drug which has shown inhibitory activity higher 
than etoposide against any eukaryotic topoisomerase II tested to date [7 6, 77]. As mentioned before, 
quinolones are known primarily for their antibacterial activity. Common features in the mechanism of 
action of antibacterial quinolones and antitumor analogs have suggested that both compounds have a 
similar mode of interaction with topoisomerase II-DNA complexes. Comparative studies between 
quinolones and epipodophyllotoxin families (etoposide and teniposide) showed that neither of them are 
DNA intercalators [78]. Further studies carried out between eukaryotes and eubacteria [79], comparing 
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the sensitivity of topoisomerase poisons against each type II topoisomerase enzyme, led to a strong 
support that a common mode of interaction with DNA-topoisomerase II enzyme complex exists for the 
quinolone (ciprofloxacin) and etoposide [79,80] . 
1.3. Synthetic Variations of Quinolones 
Decades of intensive research for the fight against resistant bacterial strains has yielded dozens 
of versatile agents for therapeutic use. Because of the need and desire for addressing the clinical 
concerns like resistance, toxicity, route of administration, frequency of dose and to increase the 
spectrum of activity, synthetic routes have been developed which resulted in enormous number of 
quinolone analogs. The major synthetic routes to the quinolone cores were recently reviewed [81]. 
1.3.1. Gould -Jacob's Synthesis 
This is a prototype based on which a number of variations have been made. This 
established method (scheme 1.1) relies on an addition-elimination reaction. 4-Quinolone is formed 
during the reaction of substituted anilines with diethyl ethoxymethylenemalonate with heat in 
Dowtherm A[82]. 
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Scheme 1.1. Gould-Jacob's Reaction 
Alkylation ofthe quinolone-4(1H)-one scaffold, followed by hydrolysis of the ester group, 
affords N-substituted 4 (IH)-quinolone-3-carboxylic acid. 
1.3.2. Grohe-Heitzer Reaction 
Novel quinolones synthesis has been expanded, to a great extent, by the introduction of the 
Grohe-Heitzer cycloacylation synthesis [83, 91]. This procedure, as shown in Scheme 1.2, begins with the 
acylation of malonate derivative with benzoyl chloride to give an acyl malonate intermediate. 
Condensation of the intermediate with an ortho-ester in the presence of a dehydrating agent such as acetic 
anhydride affords an enol ether. The enol ether then undergoes an addition-elimination sequence with an 
amme to afford 3-aryl-2-aminoacrylate. Intramolecular addition-elimination then delivers the quinolone 
core. 
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These processes establish the pharmacophoric keto acid moiety of the pyridine ring and allow for 
introduction of a wide variety of N-substituents including those possible with the Gould-Jacobs 
reaction. 
1.3.3. Camps Quinoline Synthesis 
Camps Quinoline Synthesis (Camps Cyclization) is a reaction in which an 0-
acylaminoacetophenone affords two scaffolds, 4-hydroxy- and 2-hydroxyquinolines, 
using an alkaline base as depicted in Scheme 1.3 [84-87]. 
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The structure of the starting material and the relative reaction conditions decide the relative 
proportions of the hydroxyquinolines. It is believed that the keto form predominates in both the 
solid state and in solution, thus making the product a quinolone [88]. 
1.3.4. Conrad-Limpach Synthesis 
This method involves the reaction of anilines with ~-ketoesters to form 4-hydroxyquinolines via 
a Schiff base [84, 89, 90]. The general reaction procedure is shown in Scheme 1.4. 
Scheme 1.4. Conrad-Limpach Synthesis 
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1.3.5. Gerster-Hayakawa Synthesis 
This method is a variant of the Gould-Jacobs reaction (Scheme 1.1 ). Gerster Synthesis (Scheme 
1.5): This method was initially used to produce the first fluoroquinolone, flumequine. Flumequine is the 
first chiral member of the class of fluoroquinolones [82, 91]. In Gerster synthesis, a carbocyclic analog is 
produced using appropriately substituted tetrahydroquinoline scaffold and diethyl ( ethoxymethylene) 
malonate (DEEM) by standard methods .. 
0 0 
R 
~~ ~ __ H_2----.. ~ ~ cat. N DEEM OH 
Scheme 1.5. Gerster Synthesis 
Hayakawa Synthesis, [92], (Scheme 1.6): in this variant of the Gerster-Hayakawa synthesis, 
trihalonitrobenzenes undergo alkaline hydrolysis, specifically occurring at the halogen atom adjacent to 
the nitro group to afford the corresponding nitrophenol analogs. The 2-oxopropyl ethers of these 
nitrophenol derivatives were then converted to benzoxazine derivatives by reductive cyclization. 
Condensation of benzoxazine derivatives with diethyl ( ethoxymethylene )malonate (DEEM) under heat 
affords subsequent intermediate, which upon cyclization and hydrolysis gives the corresponding acids. 
Exploitation of this method led to the ease of accessibility of oxo or thio derivatives. 
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Based on the above discussions, my attention was focused on the design, synthesis and biological 
evaluation of novel tricyclic quinolones with potential anticancer properties. The following chapters 
describe the profiles of different series of these novel molecules. 
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2.1. Structure-Activity Relationships (SAR) and Common Clinical Applications of Quinolones 
Archetypical antibacterial fluoroquinolones are the cornerstones in defining the SAR of cytotoxic 
quinolones. Systematic structural modification of prototypic antibacterial quinolones led to the 
identification of characteristic structural features essential for activity against eukaryotic cells. 
One of the major advances in this field occurred with the discovery of locus classicus, 
Norfloxacin. Inclusion of a fluorine at position 6 and a piperazinyl group at position 7 has resulted in 
broad spectrum antimicrobial activity. Figure 2.1 depicts examples of different generations of 
antimicrobial quinolones [ 1]. 
~C(tOOH I 
>io 
l,_C>io 
NalidixiC ac1d 
1,8-napthyridine 
+ 
('v i__Wcoo" 
~ l,_CI\o 
Pipem1d1c actd 
7·piperulnyl 
+ ):;(JCOOH 
(' ~ l,_C>io 
6-fluorine 
+ 
r-::c&COOH COOH ~ l,_C>io 
Norf/oxacm 
8-methoxy 
----.. 
First generation 
Second generation 
Third generation 
Fourth generation 
8-cyclo T 
Levonoxacm 
S.Cyclo 
Figure 2.1. Structures and generations of quinolones 
36 
Chapter 2: Structural Activity Relationship Review of Cytotoxic Quinolones & their uses 
Starting from this discovery to Trovafloxacin no single position could be credited to produce anti-
cancer activity. In fact, an amalgamation of various substituents at their respective positions have been 
bestowed to the concomitant cytotoxic activity. These positional modifications of the parent antibacterial 
quinolones showed that higher potency as well as broader antibacterial spectrum has occurred with the 
concomitant presence of fluorine atom at C-6 and a suitable heterocyclic base at C-7 [ 1, 2, 3]. 
The unique characteristic of bacteria, "fit for survival", has enabled them to multiply indomitably 
under inappropriate environments [4]. Despite vast research and knowledge data base, only few 
antibacterial quinolones have been authorized for clinical use. The situation is worse with anticancer 
quinolones since none is licensed for clinical use. Thus, innovative design and synthesis of anticancer and 
antibacterial quinolones is vital. Quinolone antimicrobial agents exert their antibacterial action via 
inhibition of homologous type II topoisomerases, DNA gyrase and DNA topoisomerase IV [5-7] . The 
structural features of partial quinolone-enzyme-DNA complex have been shown in Figure 2.2 [8-9]. Few 
findings report that the quinolones cause mutations in the highly conserved sites of homologous type II 
topoisomerases, also called the quinolone resistance determinin region (QRDR) [10]. Not to forget the 
presence of active efflux mechanisms that initially allow bacteria to survive [11, 12] and subsequently 
permits the development of adaptive QRDR mutations at drug target sites. There are no known reports 
suggesting the presence of enzymes which degrade the fluoroquinolone antibacterial agents. Thus, various 
quinolones have been developed with different functional groups at various positions to produce a 
molecule that could stop the resistance threat. Structure-activity relationships investigations have shown 
that some key substitutions at the quinolone ring are required for an active compound. Since interaction 
with topoisomerase II is central to the activity of both quinolones and antitumor agents, it is of interest to 
compare the structure-activity relationships studies relative to antibacterial quinolones. This chapter 
reviews some of the key aspects of structural requirements for cytotoxic quinolones based on several 
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investigations performed in relation to the anti-bacterial quinolones. Figure 2.2 shows the positional effect 
of functional groups on the activity of quinolones. 
F 
This region is 
essential for 
chelation 
with Mgl+ Ion to 
form 
a strong binding t 
Topoll. 
OH 
SMe, or may join with 
carboxyl carbon to for a 
Figure 2.2. Quinolone Skeleton with basic positional properties and Quinolone-DNA complex [9] 
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2.2. Structure-Activity Relationships Review 
1) According to quinolone anti-bacterial structure-activity relationships (SAR) studies (figure 2.2), 
N-1 position is an essential part of the enzyme-DNA binding complex [13]. Studies so far 
indicate that the cyclopropyl group at this position contributes to high potency in this class of 
compounds [14] with respect to their anti-proliferative activity. Substitution with other groups 
can presumably lower the number of molecules capable of binding to the enzyme-DNA pocket, 
and therefore reduce the potency [15, 16]. As mentioned earlier, contribution of the cyclopropyl 
moiety at the N-1 position to the anti-proliferative activity of quinolones is only possible with the 
concomitant presence of halogen at C-6 and C-8, which can be accounted for a better interference 
of quinolones with the eukaryotic topoismomerase II. These observations signify that the 
identity of the N-1 obtained from the SAR studies on antibacterial quinolone is kept intact for 
eukaryotic cell cytotoxicity, as well. Figure 2.3 illustrates structures of some antiproliferative 
quinolones and ciprofloxacin. 
OH OH 
HO HO 
CP-67,804 CP-115,953 
0 0 
OH 
CP-67,015 Ciprofloxacin 
Figure 2.3. Structures of cytotoxic 4-quinolones and Ciprofloxacin 
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2) It has been observed that the presence of a carboxylic acid group or its isosteres at the C-3 
position of quinolones is essential for antibacterial activity [17, 18]. The 3-COOH can also be 
replaced with a hydrogen without effecting the topo 2 enzyme inhibitory activity. This further 
deepened the understanding we have so far and paved the way for synthesizing new molecules. 
One of the key findings is that the introduction of a benzyl group at the 3-position increased the 
topo II inhibitory activity. The distance between the two aromatic rings is vital for retaining the 
potency, with only a methylene group as the ideal separator between the two aromatic groups. 
The activity further increased with the introduction of hydroxyl substituents into the benzyl 
group without any valid reason. The 2,6-dihydroxy benzyl derivative (WIN 64593), among the 3-
benzyl analoguous series, has shown the highest topo 2 inhibitory activity and the best in vitro 
cytotoxicity against mouse P388 leukemic cells(Figure 2.4) [17]. 
0 OH 
Win 64593 
Figure 2.4. Structure of WIN 64593 
The inhibitory activity of the compound is still retained in the absence of carboxyl group in 
contrast to the requirement of the 3-COOH group necessary for gyrase inhibition [19]. The 
introduction of 2-methyl and 2-phenyl has given some clear picture in relation to the 
conformation of the structure. While the 2-methyl substitution has retained activity its 
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Figure 2.5. Quinolones and steric hindrance 
2-phenyl analog is inactive, revealing the importance of the size of the 2-substituent. In the same 
context, it is interesting to know that the introduction of sulfur at position C-2 has shown to be 
very promising in improvement of antibacterial activity [20] as well as cytotoxicity [21] in 
eukaryotic cells (Figure 2.5). One interesting aspect of this structural modification is the 
modification of C-3 acidic moiety. In order to maintain the stable planar structure of the 
quinolone skeleton and the stability of the newly added sulfur atom, the structure has been 
condensed forming a whole new tricyclic planar structure. These analogues have been shown to 
be highly potent against a broad spectrum of bacteria including several multi-drug resistant 
strains. Two experimental isothiazoloquinolones A-65281 and A-65282 , despite the presence of 
heterocyclic aromatic ring, have been found to induce respectable DNA breakage mediated by 
calf-thymus topoisomerase II and are nearly as potent as tenoposide and also potent against broad 
spectrum of bacteria (Figure 2.6). 
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Figure 2.6. Structure of cytotoxic Isothiazoloquinolones 
Based on this observation it appears that the biochemical target appears to accommodate the 2-
methyl substituent rather than a larger group. Additionally, it can be concluded that the 3-COOH 
is not vital for activity but, if present, it should be able to attain a planar conformation with 
respect to the quinolone ring (Figure 2.4). 
3) The 4-position of the quinolone ring contains the carbonyl group and is an integral part of the 
quinolone skeleton. The tendency of Mg2+ ions towards formation of gyrase-drug-DNA ternary 
complex is well documented [22, 23]. The carbonyl group at position C-4 and the carboxylic acid 
group at C-3 form a complex with the magnesium which enhances the effective binding of the 
drug with the enzyme and DNA, inducing permanent DNA strand breakage. So far, no evidence 
of enhanced isosteric replacement has been reported at the C-4. 
4) A general requirement of the "classical quinolones" is the presence of a C-6 fluorine atom to 
induce potent antibacterial activity [24]. As mentioned above, in order to form a stabilized 
cleavage complex with topo 2, the concomitant presence of two halogens, particularly fluorine, at 
C-6 and C-8 on the quinolone skeleton is preferred. [21,25, 26] (Figure 2.7). 
42 
Chapter 2: Structural Activity Relationship Review of Cytotoxic Quinolones & their uses 
HO HO 
CP-115,953 CP-115,955 
Figure 2.7. Structures ofCP-115,953 and CP-115,955 
A direct comparison of 6-fluoro (CP-115,955) and 6,8-difluoro (CP-115,953) analogues 
indicates that removal of the C-8 fluorine decreased the ability of the quinolone to induce topo 
IT-mediated DNA cleavage by approximately 2.5-fold. Despite the decreased potency of CP-
115,955 in comparison to CP-115,953, it is still highly active against eukaryotic enzyme in D. 
melanogaster . In fact, this monofluoroquinolone was 80% as potent as etoposide [16, 27, 28]. 
However, the presence of a C-8 fluorine did not affect the potency of the drug towards DNA 
gyrase. Also, the activity of these compounds in Chinese hamster ovary cells equals the 
cytotoxicity observed towards the eukaryotic enzyme, thus confirming the importance of C-8 
fluorine in increasing the potency of quinolone derivatives against topo II enzyme in mammalian 
cells. 
5) The C-7 position has been one of the most intriguing in the research of quinolones against cancer 
cells. A number of quinolones with greatly increased potencies (relative to ofloxacin) toward 
eukaryotic systems have been reported [16, 21 , 25, 26, 29-31]. Almost all of the novel quinolones 
used against topo II have aromatic substituents in contrast to the general requirement of 
the antibacterial quinolones. Various quinolones with different substitutions have been 
synthesized and studied. In antibacterial quinolones the presence of a basic amino group in the 
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aliphatic cyclic substituent at this position is essential for antibacterial activity. These studies 
indicate a direct interaction of the enzyme with the C-7 position via an optimal substitution. 
(Figures 2.8 and 2.9). 
0 0 
CP-67,015 
0 0 
HO 
CP-67,804 
OH 
OH 
0 
WIN 57294 
0 
0 
OH 
Figure. 2.8. Structure of cytotoxic quinolones with C-7 aromatic substitutions 
Topo II, presumably has structural differences in comparison to its counterpart, bacterial DNA gyrase, due 
to the bias shown on aromatic substitution. This raises a question as to how such a smallstructural 
modifications can influence enzymatic target recognition at cellular level ? To date there is no answer, due 
to inadequate information towards the cleavage complex in the presence or absence of drugs. The 
stereospecificity of the substitution at C-7position has been one of the major discerning factors in 
influencing the potency against the mammalian enzyme. In particular, the methyl substituents at the C-7 
piperazine moiety have been reported to display greater influence. Against mammalian Topo II isomerise, 
the 3,5-dimethylpiperazinyl derivatives were active in stimulating enzyme-mediated DNA cleavage only 
in the trans configuration. On the other hand, the cis- and trans-methyl substitutions on the piperazine had 
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little effect on bacterial DNA gyrase cleavage activity, suggesting the existence of assymetric barrier only 
in the eukaryotic enzyme influencing cytotoxic quinolones interaction [32]. Similar studies corroborated 
0 0 HNl F y ~N~N S I I 'mr 
F o 
0 0 
OH 
A65281 WIN 57294 
0 0 0 0 
F F 
I OH OH 
H2N-() N N 0'6 0'6 ~ I ~ I 
A62176 A85226 
Figure 2.9. Cytotoxic Quinolone Structures with various C-7 substituents 
increased cytotoxicity with C-7 pyrrolidine substituents than piperazine substituents [33]. These 
results correlate with the previous observations made on cytotoxic quinolones [25]. These results 
signify the importance of aromatic substituent at C-7 position contributing to increased cytotoxic 
potency. In particular, the 4'-hydroxyphenyl substituent at C-7 position was imperative for 
increased potency towards the eukaryotic enzyme [14]. The starting point of these studies on 
SARis portrayed by CP-115,953, considered as one of the most potent cytotoxic quinolone so far 
(Figure 2.7) [16]. 
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2.3. Parallel Uses of Quinolones 
2.3.1. Quinolones as HIV-1 Integrase Inhibitors 
Current research on chemotherapy for HIV infection is yet to overcome the rapid emergence of 
resistant strains, high costs associated with the current treatments, and the inability of the current clinical 
regimens to eliminate the HIV infection. Quinolone HIV Integrase inhibitors could be a gateway for 
developing a promising new class of anti-retroviral drugs. Quinolines are not new to this field. HIV -1 
integrase [34-36], one of the three important enzymes targeted for treating HIV infection, is involved in 
retroviral replication signifying its importance as one of the essential targets for blocking the viral 
replication cycle. This enzyme is responsible for the penetration of viral eDNA into the host cell genome. 
This mechanism occurs in two steps: 
1) The first step occurs in the host cell cytoplasm where integrase cleaves the Guanosine-Thymine 
(GT) nucleotides from the conserved 3 ' -CAGT end. This results in nucleophilic hydroxyl groups 
at 3' ends of viral eDNA. HIV-Integrase then enters the nucleus of the host cell. 
2) Once the HIV-Integrase enters the nucleus of the host cell, it catalyzes the nucleophilic attack of 
both 3' end hydroxyls of the viral eDNA onto the host DNA, known as the strand transfer 
reaction. 
There has been immense interest in quinolone molecules due to various reasons, some being the ease of 
synthesis, low synthetic and manufacturing costs and detailed biochemical properties, etc. GS-9137 
(Figure 2.1 0) [37], Elvitegravir, a derivative of 4-quinolone-3-carboxylic acid, with its very strong 
antiretroviral properties owes its anti-HIV activity exclusively to the inhibition of the viral enzyme 
integrase[35] .The ~-keto acid constituent is considered to be prominent in its function as integrase 
inhibitors. A number of bioisosteric analogues of elvitegravir, diketopyridine [38], diketotetrazole [39], 7-
oxo-8-hydroxy-1 ,6-naphthyridine [ 40], and diketotriazole [ 41] have been reported. 
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Figure 2.10. Structure ofElvitegravir (GS-9137) and GS-9160 
Lately, a series of quinolone antibiotic-derived mv integrase inhibitors have been synthesized. 
The compound GS-9137 was identified as the most promising candidate, showing potent inhibitory 
activity against integrase-catalyzed DNA strand transfer [ 42]. GS-9160 also has selective antiviral 
activity, but has suffered a setback due to unfavourable pharmacokinetic properties (Figure 2.1 0) [ 43]. 
The 4-quinolone-3-glyoxolic acid, compound A-1, and its precursor 4-quinolone-3-carboxylic acid, 
compound B-1, also showed integrase inhibitory activity [35] (Figure 2.11) and maintain the co-planar 
structure which is a necessity for cytotoxic quinolones, thus providing a novel insight into the structural 
requirements and the binding mode of this type of inhibitor [ 40]. 
0 
0 OH 
Compound A-1 Compound B-1 
Figure 2.11. Structures of compounds A-1 and B-1 
2.3.2. As Signal Transducer and Activator of Transcription 3 (STAT3) 
The signal-transducer-and-activator-of-transcription 3 (STAT3) protein, one of the members of 
STATS transcription factor family, has been implicated in signal transduction by different cytokines, 
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growth factors and oncogenes. Hence, pharmacologically safe and effective agents that can block STAT3 
activation have a potential role in the treatment of inflammation, survival, proliferation and invasion of 
hepatocellular carcinoma [ 44]. There is reasonable evidence indicating the role of STAT3 proteins in 
carcinogenesis, thus making it a potential target for cancer therapy [45, 46]. 
Lead optimization of fluorinated quinolone (Compound C-1), involved in cell apoptosis via 
inhibition of STAT3 activation, led to the identification of compound D-1, with increase potency [ 4 7] 
(Figure 2.12). 
F 0 0 H 0 0 
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Figure 2.12. Structures of compounds C-1 and D-1 
2.3.3. Quinolones as anti-HCV Agents 
Currently, Hepatitis C Virus (HCV) infection is treated with a combination of pegylated 
interferon a-2a!b and ribavirin. Due to a limitation in the availability of these drugs there is an increase 
in attention towards the development of a number of molecules, which act by directly affecting key steps 
in the viral life-cycle. Novel small molecules that inhibit NS5B polymerase, NS3 protease and the viral 
RNA are the most frequently studied antiviral agents [48] . 
Non-structural protein 5b (NS5B) which encodes the RNA polymerase (RdRp) is one of the 
potential targets for several NS5B polymerase inhibitors and has shown promising results in clinical 
trials. 
48 
Chapter 2: Structural Activity Relationship Review of Cytotoxic Quinolones & their uses 
0~/p 
OH N'SY"(Ol 
N~HN~O H 2 
N 0 
I 
NH ~ A-782759 
Figure 2.13. Structure of A-782759 
Recently, A-782759, a 2-(1-aminoquinolone-3-yl) benzothiadiazine derivative, was identified as 
promising HCV NS5B inhibitor (Figure 2.13). In fact, A-782759 with HCV NS3 protease inhibitor, 
BILN-2061 , interferon (IFN) [49, 50] showed an additive effect to synergistic relationship in studies over 
a range of concentrations of the two drug combinations. 
2.3.4. Quinolones as Potential anti-Herpes Simplex Virus-1 (HSV) Agents 
Infections ofHSV-1 are the most frequently treated infections in everyday life for which 
acyclovir is the commonly used agent. Recently compounds E-1 and F -1 [51] (Figure 2.14 ), that are 
quino1one acylnucleoside derivatives, having high activity against HSV-1 , have been discovered. These 
quinolone derivatives, especially the acid derivatives are highly effective in reducing the viral load than 
their ester analogues. Upon further investigation of these quinolone derivatives, PNU-183792, a 3-(p-
chlorobenzyl carboxamide)-4(1H)-quinolone derivative (Figure 2.14), was found to be a competitive 
inhibitor of herpes virus polymerase in both human and animals. 
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Figure 2.14. Structures ofPNU-183792 and compounds E-1 and F-1 
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Chapter 3: Design, Synthesis & Biological Evaluation ofQuinolone-[2,3-b]thienoquinolones and Furoquinolones 
3.1. Introduction 
Quinolin-4 (!H)-ones ( 4-Quinolones) belong to a larger group of heterocycles. These scaffolds 
have been the subject of research for many groups, the proof of which is reflected in a vast number of 
reviews and journal articles dedicated towards their clinical use. The starting point of this research was 
based on the assumption that both the antibacterial quinolones and their cytotoxic analogs share a similar 
mode of interaction with type II DNA topoisomerase-DNA complexes. For example, studies have shown 
that quinolones and antitumor drugs of the epipodophyllotoxin family (etoposide and teniposide) act on a 
physiologically similar DNA toposiomerase enzyme, with quinolones acting on DNA gyrase and 
etoposide acting on topoisomerase II [1]. The last few years have witnessed the development of 
numerous novel tricyclic and tetracyclic quinolones that target mammalian topoisomerases I & II. The 
blueprint for this research has been developed by the team led by Dr. Daneshtalab [2]. Compound A 
(Figure 3.1), as described in a joint patent by Kyorin!Kyowa-Hakko, a thiazoloquinolone has been the 
basis ofthis initial research [3]. 
0 0 
~OH 
F)lANJ(s 
0 
Figure.3.1. Structure of Compound A 
Using the molecular modelling program Alchemy-3™, the sterically optimum conformation of 
compound A was determined using Molecular Mechanics Optimization (MMO) and Molecular Dynamic 
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Option methods. Based on these studies newly designed linear tricyclic quinolones with ~-diketo group 
were modelled to match the conformation of compound A (Figure 3 .2). From these, compound B was 
identifiedd for furthur studies. 
j 
Designed co111pound ( B ) Actlve co111pound ( A ) 
Two different overlays of the designed structure 
and the active compound 
~H 
F)lAN)l_S) 
d 
CompoundB 
Figure 3.2. Sterically optimized structure of Compound B 
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The objective of our research was to synthesize various analogues of compound B, such as the 
linear thieno[2,3-b] quinolones and furoquinolones and evaluate their cytotoxic profiles. 
3.2 Materials and Methods 
3.2.1 Synthesis of N-Alkylated thienoquinolones 
2,4-Difluorobenzoylchloride was used as a starting material. This compound was allowed to react 
with potassium ethyl malonate, magnesium chloride and triethylamine to afford the respective P-ketoester 
1 [4,5,6] . Scheme 3.1 represents the reaction. 
0 
~Cl F~F potassium ethyl malonate MgCI2, Et3N 
0 0 
NJ-o~ 
F~F 
1 
Scheme 3.1. Synthesis of P-ketoester 1, (2,4-difluorophenyl)acetoacetic acid ethyl ester (1) 
Compound 1 was then allowed to react with ethyl or benzyl isothiocyanate in the presence of 
potassium hydroxide and n-tetrabutylammonium bromide, as a phase transfer catalyst, followed by 
methylation using methyl iodide to afford compounds 2a and 2b, respectively. The intermediate 
compounds 2a and 2b, due to their instability, were cyclized using t-BuOK(potassium tert-butoxide) to 
afford the respective intermediate building blocks 3a and 3b [6].The resulting intermediates 3a and 3b 
were subjected to oxidation using m-CPBA to give 4a and 4b [6,7]. Compounds 4a and 4b were then 
allowed to react with ethyl mercaptoacetate and triethylamine in absolute ethanol at reflux for 5-6 h to 
afford the final compounds Sa and Sb [8], as shown in Scheme 3 .2. 
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0 0 
~0~ 
F~Njl_S__,. 
) 
3b 
~ iii) 
~0~ 
F~Njl_S__,. 
) 0 
4b 
5b 
i) KOH, n-tetrabutylarnmonium bromide, ethyl or benzyl isothiocyanate, CH3I, 18 h 
ii) t-BuOK, reflux, 18 h; iii) m-CPBA, 0 °C, DCM, 7-8 h; iv) HSCH2C02Et, Et3N, reflux, 5-6 h 
Scheme 3.2. Syntheses of compounds 3a,b, 4a,b, and 5a,b 
3.2.2. Synthesis of 0-Alkylated thienoquinolones 
3-Fluoroaniline was reacted with triethylamine and carbon disulfide in benzene. The resulting 
intermediate salt was then stirred with ethyl chloroformate at room temperature for 15 h to give the 
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starting material 3-flurophenyl isothiocyanate (6) [9]. Compound 6 upon reaction with diethyl malonate 
and sodium hydride in THF afforded salt 7. Due to the instability of compound 7, it was immediately 
allowed to react with iodomethane to give compound 8. Compound 8 upon heating at high temperature 
under vacuum yielded the cyclized compound 9. Compound 9 was then subjected to a modified 
Mitsunobu reaction as reported by Amoozgar. Z [2] using benzyl alcohol or ethyl alcohol to yield the 
respective analogues lOa and lOb, as depicted in Scheme 3.3. 
~ i) ~s ii) ~ .. F N)lS_ + F NH F N-2 I Et3N 
H 6 
./"-o o j 
iv) 
./"-o o j 
iii) uXo u~o 
F N S- + F N S/ 
I Na I 
H H 
7 8 
OH 0 R, 0 0 
v) do~ vi) do~ 
F N S/ F N S/ 
9 10 
R = CH2C6H5 (lOa), C2H 5 (lOb) 
i) CS2 Et3N, benzene; ii) CIC02Et, Et3N; iii) Diethyl malonate, NaH, THF; iv) CH3I, THF; 
v) Heating under vacuum; vi) DIAD, benzyl alcohol or ethanol, P(Ph)3 
Scheme 3.3. Syntheses of compounds 6, 7, 8, 9, lOa, and lOb 
s 
According to Amoozgar, Z., the modified Mitsunobu reaction was used m the process of 
synthesizing N-alkylated derivatives. In order to further confirm the regioselectivity of the Mitsunobu 
reaction, comparison of the products obtained by the basic alkylation method with compounds 3a and 3b 
and compounds obtained from Mitsunobu reaction (lOa and lOb) was performed. Interestingly, it was 
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found that compounds lOa and lOb were regioselectively 0-alkylated, while basic alkylation of 
compound 9 (Scheme 3.4) gave a mixture of both N-alkylated and 0-alkylated products. 
~0 0 
.DX:j + 
lOa 
OH 0 j Y-clllorid< 
0 ( 
F N S/ i) 0 0 j 
9 <iliylb~ ~0 F~N~S/ + 
lOb 
i) K2C03, DMF, 70-80°C, 8 h 
0 0 j ~0 F~NJlS/ 
N V3a 
3b 
Scheme 3.4. Basic alkylation of compound 9 
Alkylation at nitrogen succeeded only after cyclization of compound 8 as reported earlier [ 1 0]. 
Studies aimed at regioselectivity of alkylation of 4-hydroxy quinolone and naphthyridone derivatives 
using an ethylating agent [11] show that the likelihood of a charge-controlled reaction on nitrogen is 
small. 
A-2 
OH 0 j R2w~ 0 
I I .0 ...-: 
R N 
B-2 
Figure 3.3. Tautomerism of Quinolones 
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According to these studies it is assumed that deprotonation sequesters the coexisting enol form B-
2 resulting in the complete transformation of the keto form A-2 into the nucleophilic anion. The low 
electron density, caused by the overlapping of the nonbonding Pz orbital with the aromatic ring and the 
electron-deficient double bond, prevents the charge-controlled reaction at the nitrogen atom. In this 
respect, studies done on 4-hydroxy quinolones showed that in the presence of an excess base, potassium 
carbonate, and at room temperature the tautomeric equilibrium was shifted towards N-alkylation [ 11 ], and 
with increase in temperature there was an excess shift in equilibrium resulting in a higher yield of N-
alkylated products. Investigation done be Frank et a/. [ 12] on alkylation of quinolones with trim ethyl 
phosphate showed regioselective 0-alkylation in contrast to the studies done by Makara, G. et a/. This 
demonstrates that the 3-ethoxycarbonyl group plays a major role in the regioselectivity of N- and 0-
alkylation. In 3-alkoxylcarbonyl analogues the enol form is more stable in the gas phase, while in polar 
solvents the keto form predominates. This shows that for N-alkylation, the formation of an anion with 
high HOMO energy by deprotonation of 3-alkoxycarbonyl-4-oxoquinolines is required (Figure 3.3). 
Since the electron pair on the nitrogen atom in quinolones is involved in cyclic conjugation the 
possibility of interaction with electron-deficient reagents is very little, thus requiring the need for 
preliminary inonization of the N-H bond [13]. In the present scenario and in certain cases the 2- arylthio 
compounds are isolated in either 4-quinolinol or 4-quinolone forms, with the tautomeric pattern 
depending on several factors such as the solvent of crystallisation, the temperature of the sample and the 
steric bulk of the 2-alkylthio-substituent [14]. Hence, the domination of enol form due to hydrogen 
bonding with the oxygen of the carbonyl group and also due to the presence of bulky alkylthio group at 
position 2 can attribute to the selectivity of 0-alkylation at C-4. This selectivity is further confirmed by 
the proton chemical shift patterns in both the N-alkylated and 0-alkylated compounds. 
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Table 3.1. Comparision of Chemical Shifts of methylene group 
8 'H NMR Chemical Shift 
N-Alkylation 
3a (8 5.89) 
3b (8 4.61) 
0-Alkylation 
lOa (8 5.22) 
lOb (8 4.48) 
To further strengthen our point 2D NOESY for the above mentioned compounds has been 
performed, thus confirming that Mitsunobu reaction is oriented towards 0-alkylation owing to a variety 
of factors such as steric hindrance of the alkylthio group, hydrogen bonding ability of the carbonyl group 
at position 4 and the carbonyl group at position 3, etc. With this study it is shown that the previously 
reported N-alkylated products from Mitsunobu reaction are supposed to be 0-alkylated products [2]. 
Compounds lOa and lOb, the preparation of which were shown in Scheme 3.3, were oxidized to 
afford compounds lla and 11 b. The latter compounds were subjected to similar conditions as shown in 
Scheme 3.2 to afford compounds 12a and 12b (Scheme 3.5). 
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V'o o j V'o o j ~0 OH ~0 1X:(o :ccxo 
F N S/ F N s( F N S O_j 
H 0~ '0 
lOa lla 12a 
~ ~0 0 ---....... 0 0 j d) ~0 £Ceo ~ 
F N S/ F N s( F N S O_j ~ '0 H 0 
lOb lib 12b 
Scheme 3.5. Synthesis of compounds 12a and 12b 
3.2.3. Synthesis ofFuroquinolones 
Furoquinolone alkaloids are well known in nature, but so far their biological activities have not 
been well studied [15]. In order to further investigate their anti-cancer activity we synthesized and tested 
various furoquinolone analogs. In order to synthesize a series of compounds possessing furoquinolone 
scaffold, we followed the procedures reported by Shen-Chu Kuo, et al. , with minor modifications [16]. 
Namely, to a solution of sodium diethyl malonate in THF was added chloroacetyl chloride. To the 
resultant mixture was added 3-fluoroaniline to afford the intermediate 13. Intermediate 13 was added with 
stirring to Dowtherm maintained at 240 °C to afford compound 14. Compound 14 was then subjected to 
alkylation using various alkylhalides to afford compounds 15a-d. Further, compound 14 was also treated 
with phosphorus oxychloride to afford 3-chloro-7-fluoro-4-oxo-4,9-dihydrofuro[2,3-b ]quinoline-2-
carbaldehye (16), as shown in Scheme 3.6. 
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Et, 0 0 
~ i) F~J:S ii) .. F NH 2 
13 
[14] iv) .,. 
rii) 
~ 
F)lAN)L_O) 
I 
R 
ISa:R ~b ISb:R~Q 
F 
65 .. F N 0 
H 
14 
0 
F 
16 
i) a) NaH, diethyl malonate, THF b) chloroacetyl chloride, THF, 3-fluoroaniline 
ii) Dowtherm, 240-250 °C, 10 min 
iii) K2C03, BnCl (or) 4-FBnCl (or) 4-0MeBnCl (or) BrCH2CN, DMF 
iv) phosphorous oxychloride, DMF 
Scheme 3.6. Synthesis ofFuroquinolones 14, 15a-d, and 16 
3.2.4 In vitro testing 
3.2.4.1 Brine Shrimp Lethality Test 
0 
H 
Brine shrimp bioassay is an assay capable of detecting the lethality of compounds. The technique 
is simple, inexpensive, and uses small amounts of test material. The aim of the method is to provide a 
first-line screen that can be backed up by more sophisticated bioassays once the active compounds have 
been isolated. For this test, eggs of brine shrimp Artemia Salina were used. The eggs were aerated in lL 
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capacity box containing imitation sea water (composed of sodium chloride and sodium bicarbonate). An 
air pipe is inserted to ensure complete hydration of the cysts. After 24 h of incubation under a lamp at 
room temperature (25-29 °C), newly hatched free-swimming nauplii were harvested from the bottom 
outlet. As the cyst capsules float on the surface, this collection method ensured pure harvest of nauplii. 
The freshly hatched free-swimming nauplii were used for the bioassay. The assay system was prepared 
with 2 mL of filtered saline water containing chosen concentration (0.1 f.!g/mL, 1 f.!g/mL, 10 f.!g/mL, 100 
f.!g/mL ) of compounds to be tested. Parallel vehicle control (using 2% DMSO) and negative control 
(without vehicle) were included in the experimental setup. In each, 20 nauplii were transferred and the 
setup was allowed to remain for 24 hours, under constant illumination. After 24 h, the dead nauplii were 
counted with a hand lens. Based on the percent mortality, the LD50 of the test compounds were 
determined by probit analysis according to Finney [ 17]. 
% mortality= NofNL X 100 
(Nn= No. of dead nauplii ; NL;::;; No. of live nauplii) 
3.2.4.2. MTT Cytotoxicity Bioassay 
MTT (3-( 4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity test is a 
colorimetric assay for measuring the activity of cellular enzymes that reduce the tetrazolium dye, MTT, 
to insoluble purple coloured formazan. This assay measures cellular metabolic activity via NAD(P)H-
dependent cellular oxidoreductase enzymes and may, under defmed conditions, reflect the number of 
viable cells (cell proliferation). 
NADPH 
mitochondrial enzyme 
MIT, yellow 
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Most of the potentially cytotoxic compounds were preliminary tested against HeLa and KB cell 
lines using this bioassay [ 18]. 
He La cells were grown m DMEM with 15% FBS and antibiotics (penicillin 100 U/mL, 
streptomycin 100 Jlg/ml) at 37 °C in a humidified, 5% carbon dioxide atmosphere. The cells were then 
tripsinised and seeded into standard 96-well cell culture plates. After 16 h incubation the cells were 
treated with respective test compounds for 48 h at concentrations of 0.1, 1, 10, 100 Jlg/ml). In parallel, 
controls with equivalent concentrations to the respective serial dilutions of the test compounds are 
maintained. A solubilization solvent usually DMSO, an acidified ethanol solution, or a solution of the 
detergent sodium dodecyl sulfate in diluted hydrochloric acid is added to dissolve the insoluble purple 
formazan product into a colored solution. The absorbance of this colored solution is quantified by 
measuring at 570 nm by a spectrophotometer. The absorption maximum is dependent on the solvent 
employed. 
3.3. Results and Discussion 
In Brine shrimp lethality test, compounds Sa, Sb, 12a, 12b, 15a, 15b, 15c, 15d and 16 have been 
shown to be 100% cytotoxic compared to taxol as a reference standard. These compounds at all the 
concentrations of 0.1 , 1, 10 and 100 Jlg/ml have killed all the nauplii. Based on these positive results in 
order to study further the potential of these compounds, three compounds, namely an 0-benzylated, a N-
ethylated, and a N-benzylated derivatives, were selected and sent to Taiho Pharmaceutical Co Ltd. (Japan) 
and Naeja pharmaceuticals in Edmonton for more rigorous testing on representative solid cancer cell 
lines. The results of these tests are described in the Table 3 .2. 
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Table 3.2. Cytotoxic activity of compounds Sa and Sb nad 12a against Kb and HeLa cell lines 
Compound Kb-ICso (f.lM) HeLa-ICso(f.lM) 
Sa >50 90 
Sb -- >100 
12a 24.7 --
Based on the above cytotoxicity results, it is hypothesized that the N-alkylated compounds (Sa and 
Sb) did not display reasonable cytotoxicity against both cell lines, while compound 12a (the 0-benzylated 
analog exhibited mild cytotoxicity against Kb cell line. 
3.4. Conclusion 
Quinoline scaffold is considered as a privileged scaffold in cancer drug discovery. Novel 
quinoline derivatives were designed as anticancer iron chelators. This scaffold has been the subject of 
various studies which triggered the synthesis of a series of new molecules that display different biological 
activities. A series of thieno- and furoquinolones have been developed based on the structure of 
compound B. Despite the lack of reasonable cytotoxic potency in these compounds, this study has shed 
light on a novel series of quinolones that have the potential of being studied as early leads to discover 
novel antitumor agents. 
3.S. Experimental 
All chemicals were supplied by Sigma-Aldrich Canada. All commercially available reagents were 
used without purification. Solvents were used as obtained from the supplier unless otherwise stated. 
Organic solutions were dried over anhydrous sodium sulfate, filtered, and concentrated with a Buchi 
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rotary evaporator at reduced pressure. Melting points were recorded by open tube capillary method on a 
Thomas-Hoover capillary apparatus and are uncorrected. 1H-NMR and 13C-NMR spectra were recorded 
on 500 MHz or 300 MHz Burker AVANCE spectrometers using DMSO-d6, CDCh, acetone-d6 or TFA-d 
as solvents. Chemical shifts were given in ppm (8) using TMS as an internal standard, and the spectral 
data were consistent with the assigned structures. Coupling constants (J) were given in Hz. Mass spectra 
were recorded on Agilent 1100 series LC/MSD chromatographic system. High resolution mass spectra (EI 
I ESI) were obtained on a Waters GCT Premier Micromass spectrometer. Silicycle Ultrapure silica gel (0-
20 11m) G and F-254 were used for the preparative-layer TLC, and Silicycle Ultrapure Flash silica gel ( 40-
63 11m) was used for flash column chromatography. Commercial precoated silica gel plastic sheets 
(Polygram SIL GIUV254) were used for thin layer chromatography (TLC). TLC was performed to 
monitor progress of the reaction and purity of the synthesized compounds, spots being located using UV-
light. Yields are of purified product and are not optimized. 
Ethyl 3-(2,4-difluorophenyl)-3-oxopropanoate (1) : 
A mixture of potassium ethylrnalonate (13.39 g, 76.97 mmol) and magnesium chloride (16.41 g, 172.41 
mmol) in acetonitrile (150 mL) was stirred under nitrogen for 30 min at room temperature. Triethylamine 
(17.19 g,169.92 mmol) was then added dropwise to the reaction mixture, and the mixture was stirred for 
2h. To this mixture, a solution of acetonitrile (20 mL) containing 2,4-difluorobenzoyl chloride (10.00 g, 
56.64 mmol) was added dropwise at 5-10 °C over approximately 10 min . The reaction mixture was 
stirred for 2 h at room temperature and 1 mL of triethylamine was then added to the reaction mixture and 
was stirred at room temperature overnight. The solvent was then removed under vacuum and toluene was 
added. The reaction mixture was then acidified with 6N HCl and mixed vigorously. The organic layer 
was separated, washed with water (100 mL x 2) followed by brine solution. The organic layer was dried 
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over sodium sulfate and evaporated under vacuum to afford compound 1 as a colorless oil (10.985 g, 
85%). 
1H NMR (CDCh, 300 MHz) 8: 8.08-7.98 (lH, m)), 7.01-6.59 (lH, m), 6.90-6.86 (lH, m), 4.26-4.19 ( 
2H, q, J= 7.5 Hz), 3.98-3.95 (2H, q, J= 7.5 Hz), 1.29-1.25 (3H, t, J= 7.0 Hz). APCI-MS (+ve mode): 
(m/z) 229.0 ([M+H]\ 100). 
E thy I (2Z)-3-(benzylamino )-2-[ (2,4-difluo ro phenyl)carbo nyl]-3-( methylsulfanyl)-
prop-2-enoate (2a) : 
A mixture of compound 1 (5.00 g, 21.9lmmol), potassium hydroxide (1.51 g, 6.62 mmol), and n-
tetrabutylammonium bromide (7 mg, 0.21 mmol) in dimethylformamide (DMF) (50 mL) was stirred for 
30 min at room temperature. The mixture was then cooled to 0 °C, and to it was added benzyl 
isothiocyanate dropwise (4.90 g, 32.9 mmol). After the mixture being stirred for 16 h at room 
temperature, iodomethane (3.449 g, 24.38 mmol) was added to it and the stirring was continued for 
additional 3 h. The reaction mixture was quenched with water (100 mL) and saturated aq. ammonium 
chloride (70 mL) and extracted with ethyl acetate (AcOEt) (2 X 50 mL). The combined organic layers 
were washed with water (30 mL) and brine (30 mL) and evaporated to dryness under reduced pressure. 
An analytical sample (viscous yellow liquid) was obtained via column chromatography purification on 
silica gel (eluent: 0-20% v/v AcOEt in hexanes). 1H NMR (CHCb d3, 500 MHz) 8: 11.71 (lH, s), 7.53-
7.47 (lH, m), 7.39-7.30 (5H, m), 6.90-6.86 (lH, m), 6.80-6.76 (lH, m), 4.81 (2H, J= 6.7 Hz), 3.96-3.92 
(2H, m), 2.44 (3H, s), 0.94-0.91 (3H, t, J= 6.5 Hz). APCI-MS (+ve mode): (m/z) 392.1 ([M+H]+, 100). 
Ethyl (2Z)-2-[ (2,4-difluorophenyl)carbonyl]-3-( ethylamino )-3-( methylsulfanyl)-prop-2-enoate (2 b): 
A mixture of compound 1 (5 .00 g, 21.91 mmol), potassium hydroxide (1.51 g, 31.68 mmol), and n-
tetrabutylmmonium bromide (7 mg, 0.21 mmol) in DMF (50 mL) was stirred for 30 min at room 
temperature. The mixture was then cooled to 0 °C, and to it was added ethyl isothiocyanate dropwise 
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(2.86 g, 32.9 mmol). After stirring the mixture for 16 hat room temperature, iodomethane (3.449 g, 24.38 
mmol) was added to the reaction mixture and continued stirring for additional 3 h. The reaction mixture 
was quenched with water (100 mL) and saturated aq. ammonium chloride (70 ml) and extracted with 
AcOEt (2 X 50 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL) 
and evaporated to dryness under reduced pressure. A viscous liquid was obtained via column 
chromatography purification on silica gel (eluent: 0-15% v/v EtOAc in hexanes). 1H NMR (CDCb, 500 
MHz) 8: 11.60 (s, 1H), 7.48-7.45 (m, 1H), 6.89-6.86 (m, 1H), 6.78-6.75 (m, 1H), 3.94-3.90 (q, J = 6.3 
Hz, 2H), 3.66-3.62 (q, J = 6 .. 1 Hz, 2H), 2.48 (s, 3H), 1.35-1.32 (t, J = 5.9 Hz, 3H), 0.93-0.89 (t, 3H). 
APCI-MS (+ve mode): (mlz) 330.1 ([M+Ht, 100). 
Ethyl 1-benzyl-7 -fluoro-2-( methylsulfanyl)-4-oxo-1,4-dihydroq uinoline-3-carboxylate (3a) : 
Potassiun-tert-butoxide (t-BuOK) (1.10 g, 9.69 mmol) was added to a solution of compound 2 (3.161 g, 
8.077 mmol) in toluene (25 mL) at room temperature. The resulting mixture was refluxed for 16 h, 
cooled to room temperature, and diluted with water (100 mL). The aqueous layer was separated and 
extracted with EtOAc (20 mL). The combined organic layers were washed with water (30 mL) and brine 
(30 mL), then evaporated to dryness. The crude compound was purified using column chromatography 
(eluent: 0-40% EtOAc in Hexanes). 1H NMR (CDC13, 500 MHz) 8: 8.45 (dd, J= 7.5 Hz, 1H,), 7.34 (m, 
3H), 7.06 (4H, m), 5.89 (2H, s), 4.46 (q, J = 5.9 Hz, 2H,), 2.42 (3H, s), 1.42 (3H, J = 6.3 Hz, t); 13C 
NMR (CDCb, 500 MHz) 8: 173.19, 167.19, 165.78, 163.84, 148.52, 143.11, 142.95, 135.25, 130.15, 
130.01 , 129.37, 128.13, 127.24, 123.77, 113.45, 104.15, 61.87, 52.42, 20.61 , 14.20. APCI-MS (+ve 
mode): (m/z) 371.2 ([M+Ht, 100); HR-MS (Ef): calcd for C20H18FN03S (371.4319); found (371.0989). 
Ethyl 1-ethyl-7 -fluoro-2-(methylsulfanyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3b) : 
tert-BuOK (1.10 g, 9.69 mmol) was added to a solution of compound 3 (2.66 g, 8.077 mmol) in toluene 
(25 mL) at room temperature. The resulting mixture was refluxed for 16 h, cooled to room temperature, 
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and diluted with water (100 mL). The aqueous layer was separated and extracted with AcOEt (20 rnL). 
The combined organic layers were washed with water (30 rnL) and brine (30 rnL), then evaporated to 
dryness. The crude compound was then purified using column chromatography (eluent: 0-40% EtOAc in 
hexanes). 1H NMR (CDCb, 500 MHz) 8: 8.45 (lH, J= 6.71 Hz, J= 8.95 Hz, dd), 7.21 (1H, J= 11.2 Hz, 
J=2.1 Hz,dd), 7.11 (1H, J=9.1 Hz, J=7.9Hz,J=2.2Hzddd),4.61 (2H, J=28.4Hz, d),4.44(2H,J 
= 7.14 Hz, q), 2.60(3H, s), 1.47 (3H, J= 7.1 Hz, t), 1.41(3H, J= 9.1 Hz, J= 5.3 Hz, dd); 13C NMR 
(CDCb, 500 MHz) 8: 173.28, 167.28, 165.89, 163.93, 147.68, 142.25, 130.37, 126.96, 123.86, 113.14, 
103.02, 61.76, 44.13 , 20.77, 143.38. APCI-MS (+ve mode): (mlz) 310.03 ([M+Ht, 100); HR-MS (E.f): 
calcd for C15H16FN03S (309.3558); found (309.0831). 
Ethyl 1-benzyl-7 -fluoro-2-(methylsulfinyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate ( 4a) : 
To a solution of compound 4 (1.50 g, 3.83 mmol) in DCM (5 mL) at 0 °C was added MCPBA (1.189 g, 
6.894 mmol) and the reaction mixture was allowed to stir at room temperature for 7-8 h. It was then 
neutralized using 3% sodium bicarbonate solution (10 mL) and washed with brine solution. The organic 
layer was separated, dried over sodium sulfate and evaporated under vacuum to give a colorless viscous 
liquid, which was then purified using column chromatography (eluent: 0-80% EtOAc in hexane) to give a 
white amorphous powder (0.415g, 28%). 1H NMR (CDCh, 500 MHz) 8: 8.48-8.45 (m, 1H), 7.39-7.31 
(m, 3H), 7.15-7.12 (m, 1H), 7.06-7.02 (m, 3H), 6.12-5.99 (dd, J = 8.0 Hz, J = 9.3 Hz, 2H), 4.47-4.42 (q, 
J = 5.8 Hz, 2H), 2.95 (s, 3H), 1.46-1.40(t, J = 6.3 Hz, 3H). APCI-MS (+ve mode): (m/z) 388.01 
((M+Ht, 100). 
Ethyl 1-ethyl-7-fluoro-2-(methylsulfinyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate ( 4b) : 
To a solution of compound 5 (2.00 g, 6.46 mmol) in DCM (10 rnL) at 0 °C was added MCPBA (1.95 g, 
11.30 mmol) and the reaction mixture was allowed to stir at room temperature for 7-8 h. It was then 
neutralized using 3% sodium bicarbonate solution (10 ml) then washed with brine solution. The organic 
layer was separated, dried over sodium sulfate and evaporated under vacuum to give a colorless viscous 
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liquid, which was then purified under column chromatography (eluent: 0-80% EtOAc in hexane) to give a 
white amorphous powder (0.530g, 25.2%). 1H NMR (CDCb, 500 MHz) 8: 8.49-8.41 (m, J= 8.5 Hz, J= 
11.5 Hz, 1H), 7.25-7.13 (m, 2H), 4.69-4.62 (q, J= 8Hz, 2H), 4.45-4.41 (q, J= 7.5 Hz, 2H), 3.22 (s, 3H), 
1.53-1.51 (t, J = 7.6 Hz, 3H), 1.40-1.38 (t, J = 7.5 Hz, 3H). APCI-MS (+ve mode): (mlz) 326.0 
([M+Ht, 100). 
Ethyl 9-benzyl-7-fluoro-3-hydroxy-4-oxo-4,9-dihydrothieno[2,3-b ]quinoline-2-carboxylate (Sa) : 
A mixture of compound 4a (1.00 g, 2.58 mmol), ethyl mercaptoacetate (2.58 mmol), triethylamine (7.74 
mmol) in anhydrous ethanol (30 mL) was refluxed for 5 h under nitrogen atmosphere. The solvent was 
evaporated to dryness under reduced pressure, water was added (8 mL) and the solid obtained was 
collected by filtration. Further purification accomplished by recrystallization from ethanol/water gave a 
yellow powder (5%). Mp: 140-143 °C. 1H NMR (CDCb, 500 MHz) 8: 11.11 (s, 1H), 8.52-8.49 (m, 1H), 
7.39-7.33 (m, 3H), 7.18-7.10 (m, 3H), 7.07-7.00 (m, 1H), 5.43 (s, 2H), 4.38-4.33 (q, J = 6.0 Hz, 2H), 
1.39-1.36 (t, J = 6.5 Hz, 3H). 
APCI-MS (+ve mode): (m/z) 397.01 ([M+Ht, 100). 
Ethyl 9-ethyl-7-fluoro-3-hydroxy-4-oxo-4,9-dihydrothieno[2,3-b]quinoline-2-carboxylate (Sb) : 
A mixture of compound4b ( 1.20 g, 3.68 mmol), ethyl mercaptoacetate (3 .68 mmol), triethylamine (11 .04 
mmol) in anhydrous ethanol (30 mL) was refluxed for 5 h under nitrogen atmosphere. The solvent was 
evaporated to dryness under reduced pressure, water was added (8 mL) and the solid obtained was 
collected by filtration. Further purification accomplished by recrystallization from ethanol/water to give a 
yellow powder (5%). Mp: 118-120 °C. 1H NMR (CDCb, 500 MHz) 8: 11.15 (s, 1H), 8.51-8.43 (m, 1H), 
7.20-7.10 (m, 2H), 4.43-4.33 (q, J = 7.8 Hz, 2H), 4.32-4.22 (q, J= 7.6 Hz, 2H), 1.59-1.49 (t, J= 7.5 Hz, 
3H), 1.45-1.35 (t, J= 7.4 Hz, 3H). APCI- MS: (m/z) 335 ([M+Ht, 100). 
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3-Fiuorophenyllsothiocyanate (6): 
To a stirred solution of25 .00 g (224.98 mmol) of 3-fluoroaniline and triethylamine (68.303 g, 675 mmol) 
was added carbon disulfide (18.84 g, 247.5 mmol) dropwise under ice cooling. The reaction mixture was 
kept under ice-cooling overnight. The resulting precipitate was collected by filtration, washed with 
toluene, and dried to give triethylarnmonium (3-fluorophenyl)dithiocarbamate (61.42 g, 90%,) as a pale 
yellow powder, which, without further purification, was suspended in 150 mL of CHCh and (23 . 779 g, 
235 mmol) of triethylamine. To this suspension was added dropwise 25.513 g (235.1 mmol) of ethyl 
chloroformate with stirring under ice cooling. After stirring at room temperature for 15 h, the reaction 
mixture was poured into ice-water and extracted with n-hexane. The organic layer was washed with dilute 
aqueous HCl and water, then dried over sodium sulfate and concentrated to dryness under reduced 
pressure to afford a crude oil, which was chromatographed on silica gel with n-hexane to give (22.817 g, 
69.7%) of 3-fluorophenyl isothiocyanate (6). 1H NMR (CDCh, 500 MHz) o: 7.34-7.29 (m, 1H), 7.04-
6.95 (m, 2H), 6.96-6.92 (m, 1H). APCI- MS: (m/z) 154.06 ([M+H]\ 100). 
Diethyl {[(3-fluorophenyl)amino](methylsulfanyl)methylidene}propanedioate (8): 
To a stirred suspension of (3.655 g, 145.05 mmol) NaH 95% in 150 mL of tetrahydrofuran (THF) 
maintained at 5 °C was added dropwise 23.232 g (145.05 mmol) of diethyl malonate for 15 min. After 
stirring at room temperature for 30 min (22.00 g, 143.62 mmol) of 3-fluorophenyl isothiocyanate in THF 
(80 mL) was added gradually to this mixture under ice cooling. The reaction mixture was allowed to stand 
at 4 °C for 15 h. The resulting precipitate was collected by filtration, washed with ether, and dried to 
afford the sodium salt of diethyl [[(3-fluorophenyl)amino] thiomethyl]-malonate (7) ( 40.934 g, 85% ). To 
a solution of sodium salt (7) in DMF (120 mL) was added dropwise 34.661 g (244.2 mmol) of methyl 
iodide under ice cooling. After stirring at the same condition for 1.5 h, the reaction mixture was warmed 
gradually to room temperature and was stirred for an additional 2 h. The reaction mixture was then poured 
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into water and extracted with DCM. The organic layer was washed with water, dried over sodium sulfate, 
and concentrated to dryness under reduced pressure. The residue was chromatographed on silica gel with 
n-hexane to give compound 8 (25.967 g, 65%). 1H NMR (CDCb, 500 MHz) 8: 10.53 (s, 1H), 7.15-7.07 
(m, 2H), 6.89-6.52 (m, 2H), 4.42-4.11 (m, 4H), 2.01 (s, 3H), 1.37-1.25 (m, 6H). 
Ethyl 7-fluoro-4-hydroxy-2-[(thiomethyl)] quinoline-3-carboxylate (9): 
Pure compound 8 (23.03 g, 70.35 mmol), was heated at 180 °C under vaccum for 10-15 min. The 
reaction mixture was then left to cool down to room temperature giving a solid precipitate, which was 
then recrystallized from AcOEtlhexane to give compound 9 as an amorphous powder (10.729 g, 40%). 
Mp: 121-123 °C. 1H NMR (CDCb, 500 MHz) 8: 13.31 (s, 1H), 8.21-8.19 (dd, J =5.0 Hz, J= 11.0 Hz, 
1H), 7.43-7.32 (dd, J = 2.8 Hz, J= 11.0 Hz), 1H), 7.16-7.05 (dd, J= 3.8 Hz, J = 9.0 Hz, 1H), 4.57-4.52 
(q, J= 8.0 Hz, 2H), 2.58 (s, 3H), 1.55-1.52 (t, J = 8.0 Hz, 3H). APCI-MS (+ve mode): (m/z) 282.01 
([M+Ht, 1 00). 
Ethyl 4-(benzyloxy)-7-fluoro-2-(methylsulfanyl)quinoline-3-carboxylate (lOa): 
Method 1: To a solution of compound 9 (5 .00 g, 17.77 mmol) and potassium carbonate (4.893 g, 35.4 
mmol) in DMF (50 mL) was added benzyl bromide (6.054 g, 35.4 mmol) and the mixture was allowed to 
stir at 70-80 °C for 8 h. The reaction mixture was then warmed to room temperature, washed with water, 
and extracted with DCM. The organic extract was then dried over sodium sulfate and filtered. The filtrate 
was evaporated under reduced pressure to give a crude compound which was purified by column 
chromatography (0.5% AcOEt in hexane) to give compound lOa as a pale yellow highly viscous oil (2.64 
g, 40%). 
Method 2 (Modified Mitsunobu): To a solution of compound 9 (3.5 g, 12.44 mmol) triphenylphosphine 
(3 .92 g , 14.93 mmol) and benzyl alcohol (1.35 g , 12.44 mmol) in THF (lOrn!), diisopropyl 
78 
Chapter 3: Design, Synthesis & Biological Evaluation ofQuinolone-[2,3-b]thienoquinolones and Furoquinolones 
azodicarboxylate (DIAD) (3.02 g, 14.93 mmol) was added dropwise. The reaction mixture was stirred for 
6 hours. After the removal of the solvent under reduced pressure, anhydrous diethyl ether was added and 
allowed to stand for 5 hrs, then filtered. The diethyl ether was then evaporated under reduced pressure and 
the oily residue was purified by silica gel column chromatography (0.5% AcOEt in hexane) to give 
compound lOa as a pale yellow highly viscous oil (0.69 g, 15%). 1H NMR (CDCh, 500 MHz) &: 7.99 
(dd, 1H, J= 9.1 Hz, J= 6.1 Hz), 7.54 (dd, 1H, J= 10.1 Hz, J= 2.5 Hz), 7.41 (5H, m), 7.1 5 (ddd, 1H, J= 
9.1 Hz, J = 8.3 Hz, J = 2.5 Hz), 5.22 (2H, s), 4.45 (2H, m), 2.68 (3H, s), 1.41(t, 3H, J = 7.2Hz) ; 13C 
NMR (CDCb, 500 MHz) &: 166.13, 166.00, 162.67, 159.99, 159.88, 150.58, 150.41, 135.95, 128.73, 
128.01, 125.47, 125.33, 117.84, 116.14, 115.54, 115.21 , 112.23, 111.96, 62.30, 14.08. APCI-MS (+ve 
mode): (m/z) 372.08 ([M+Ht, 100); HR-MS (Ef} calcd for C20H18FN03S (371.4252); found (371.0992). 
Ethyl 4-ethoxy-7-fluoro-2-(methylsulfanyl)quinoline-3-carboxylate (lOb): 
To a solution of compound 9 (5.00 g, 17.77 mmol) and potassium carbonate (4.893 g, 35.4 mmol) in 
DMF (50 mL) was added ethyl bromide (5 .52 1 g, 35.4mmol) and the reaction mixture was allowed to stir 
at 70-80 °C for 8 h. The reaction mixture was then warmed to room temperature, washed with water and 
extracted with DCM. The organic extract was dried over sodium sulfate and filtered. The filtrate was 
evaporated under reduced pressure on rotavapor to give crude compound which was then purified by 
column chromatography (0.5% AcOEt in hexane) to give compound lOb as a pale yellow highly viscous 
oil (2.64 g, 45%). 
Using the method 2 procedure as outlined for preparing lOa, compound lOb was prepared using 
compound 9 (2.8 g, 9.96 mmol), ethyl alcohol (0.458g, 9 .96 mmol), triphenylphosphine (3.13 g,11.95 
mmol), DIAD (2.42 g, 11.95 mmol), THF (8 ml), with a yield of 13% (0.4 g) as a yellow viscous oil. 1H 
NMR (CDCh, 500 MHz) &: 8.06 (dd, 1H,J= 9.1 Hz, J= 6.2 Hz), 7.53 (dd, 1H, J= 10.1 Hz, J= 2.4 Hz), 
7.19 (ddd, lH, J= 9.0 Hz, J = 8.4 Hz, J = 2.5 Hz), 4.48 (q, 2H, J = 7. 1 Hz), 4.27 (q, 2H, J= 7.0 Hz), 2.66 
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(3H, s), 1.46 (dt, 6H, J = 12.2 Hz, J= 7.1 Hz). APCI-MS (+ve mode): (m/z)310.08 ([M+Ht, 100); HR-
MS (Ef} calcd for C 15H 16FN03S (309.3558); found (309.0838). 
Ethyl 4-(benzyloxy)-7-fluoro-2-(methylsulfonyl)quinoline-3-carboxylate ( lla ): 
To a solution of compound lOa (1.50 g, 4.04 mmol) in DCM (1 0 mL) at 0-5 °C was added MCPBA 
[60%] (0.962 g, 5.58 mmol) and the mixture was allowed to stir overnight. The reaction mixture was then 
washed with 30% sodium bicarbonate solution (10 mL) and the organic layer was then dried over sodium 
sulfate and filtered. The filtrate was evaporated to give a white amorphous solid, which was then 
purified with 7% AcOEtlhexane using column chromatography to give compound lla as a white 
amorphous powder (0.675 g, 45%). 1H NMR (CDC13, 500 MHz) 8: 8.15-8.13 (m 1H), 7.85-7.75 (m, 1H), 
7.53-7.41 (m, 6H), 5.35 (s, 2H), 4.52-4.48 (q, J= 7.5 Hz, 2H), 3.42 (s, 3H), 1.50-1.41 (t, J= 7.2 Hz, 3H). 
APCI-MS (+ve mode): (m/z) 404.01 ([M+Hf, 100) 
Ethyl4-ethoxy-7-fluoro-2-(methylsulfonyl)quinoline-3-carboxylate ( llb ): 
To a solution of compound lOb (1.50 g, 4.85 mmol) in dichloromethane (8 mL) at 0-5 °C was added 
MCPBA [60%] (0.962 g, 5.58 mmol) and the mixture was allowed to stir overnight. The reaction mixture 
was then washed with 30% sodium bicarbonate solution (10 mL) and the organic layer was dried over 
sodium sulfate and filtered. The filtrate was evaporated to give a white amorphous solid, which was 
purified with 7% AcOEt/hexane using column chromatography to give compound llb as a white 
amorphous powder (35-40%). This compound was used in further step. APCI-MS (+ve mode): (m/z) 
326.03 [M+Ht, 1 00). 
Ethyl4-(benzyloxy)-7-fluoro-3-hydroxythieno[2,3-b]quinoline-2-carboxylate (12a) : 
A mixture of compound lla (3 .00 g, 7.436 mmol), ethyl mercaptoacetate (1.00 mmol), Et3N (3 .00 
mmol) in anhydrous ethanol (30 mL) was retluxed for 5 h under nitrogen atmosphere. The solvent was 
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evaporated to dryness under reduced pressure, water was added (8 mL) and the solid obtained was 
collected by filtration. Further purification accomplished by recrystallization from ethanoVwater gave 
compound 12a as yellow crystals (5%) M.P =135 °C. 1H NMR (CDCh, 500 MHz) o: 11.14 (s, 1H), 8.21-
8.18 (dd, J= 6.20 Hz, J= 9.30 Hz, 1H), 7.66-7.64 (dd, J= 2.4 Hz, J= 10.1 Hz, 1H), 7.50-7.38 (m, 5H), 
7.24-7.20 (m, 1H), 5.50 (s, 2H), 4.50-4.45 (q, J=7.0 Hz, 2H), 1.47-1.46 (t, J= 7.1 Hz, 3H). APCI-MS 
(+ ve mode) :(m/z) 398.10 ([M+Ht, 100); HR-MS (Er): calcd for C21Hl6FN04S(397.4194); found 
(397 .0786). 
Ethyl 4-( ethoxy)-7-fluoro-3-hydroxythieno[2,3-b ]quinoline-2-carboxylate (12b) : 
A mixture of compound llb (3.00 g, 9.2 mmol), ethyl mercaptoacetate (1.00 mmol), Et3N (3.00 mmol) in 
anhydrous ethanol (30 mL) was refluxed for 5 h under nitrogen atmosphere. The solvent was evaporated 
to dryness under reduced pressure, water was added (8 mL) and the solid obtained was collected by 
filtration. Further purification accomplished by recrystallization from ethanoVwater to obtain compound 
12b (0.177 g, 5% Yield) M.P = 120-125 °C. 1H NMR (CDCh, 500 MHz) o: 11.02 (s, 1 H), 8.39-8.34 (m, 
1H), 7.67-7.63 (m, IH), 7.33-7.28 (m, IH), 4.59-4.53 (q, J= 7.5 Hz, 2H), 4.48-4.42 (q, J= 7.2 Hz, 2H), 
1.58-1.53 (t, J= 7.1 Hz, 3H), 1.46-1.42 (t, J= 7.5 Hz, 3H). APCI-MS (+ve mode): (m/z) 336.2 ([M+Ht, 
100). 
Ethyl 2-[ (3-fluorophenyl)amino ]-4-oxo-4,5-dihydrofuran-3-carboxylate (13): 
Sodium hydride (4.35 g, 179.98 mmol) washed with dry n-hexane, was suspended in anhydrous THF (80 
mL) and a solution of diethyl malonate (28.827 g, 179.98 mmol) in THF was added drop-wise. The clear 
salt was transferred to dropping funnel, and added drop-wise to a solution of chloroacetylchloride (10.839 
g, 95.98 mmol) in THF (180 mL) over a period of I h. The reaction mixture was stirred for 2.5 h. 
Triethylamine (24.224 g, 239.4 mmol) was added to the reaction mixture and it was stirred for 2 h. 3-
Fluoroaniline (10.00 g, 89.99 mmol) in anhydrous THF (500 mL) was then added drop-wise over a period 
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of 1 h. The reaction mixture was stirred overnight, THF was evaporated in vacuo, followed by the 
addition of water and extraction with chloroform. The organic layer was washed with water and dried 
over sodium sulfate. Chloroform was evaporated under vacuum and the residue was triturated with ether, 
filtered and washed with additional ether to yield compound 13 as an amorphous solid (10.98 g, 46 % 
yield). Mp: 160-165 °C. 1H NMR (CDCb, 300 MHz) 8: 10.33 (s, lH), 7.36 (m, lH), 7.21 (m, lH), 7.12 
(m, lH), 6.95 (s, 1H), 4.72 (s, 2H), 4.39 (q, J= 7.3 Hz, 2H), 1.40 (t, J= 6.2 Hz, 3H). APCI-MS (+ve 
mode): (mlz) 266 ([M+Ht, 100). 
7 -Fluorofuro[2,3-b] q uinoline-3,4(2H,9H)-dione (14) : 
Compound 13 (5.00 g, 18.85 mmol) was added with stirring in one pot to Dowtherm (50 mL) which was 
maintained at 240 °C. The temperature was then raised to 255 °C and maintained for 10 min. The mixture 
was then cooled to room temperature and diluted with a large volume of hexane to precipitate a dark solid 
that was collected and washed with hot hexane. Yield of the crude product was 2.065 g (50% yield). 1H 
NMR (DMSO-d6 300 MHz) 8 : 13.32 (s, 1H), 8.15 (m, 1H,), 7.27-7.2 (m, 2H), 4.84 (s, lH). APCI-MS 
(+ve mode): (m/z) 220 ([M+Ht, 100). 
9-Benzyl-7-fluorofuro[2,3-b]quinoline-3,4 (2H,9H)-dione (15a): 
To a solution of compound 14 (4.00 g, 18.24 mmol) and potassium carbonate (3.782 g, 27.36 mmol) in 
DMF (40 mL) was added benzyl chloride (4.617 g, 36.48 mmol) dropwise and the reaction mixture was 
stirred at 70-80 °C for 7-8 h. The reaction mixture was then allowed to cool to room temperature, washed 
with cold water and extracted with DCM. The organic extract was dried over sodium sulfate and the 
solvent was evaporated under vacuum to give a dark brown solid. It was then recrystallized in 
DCM/hexane to give compound 15a as a dark brown amorphous solid (0.560 g, 10% yield). Mp > 200 °C. 
1H NMR (CDCb, 300 MHz) 8: 8.47 (m, 1H), 7.42-7.35 (m, 3H), 7.24 (m, 2H), 7.04 (m, 2H), 5.44 (s, 
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1H), 4.81 (s, 2H). APCI-MS (+ve mode): (m/s) 310.3 ([M+Ht, 100); HR-MS (Ef} calcd for 
CisH12FN03 (309.2911); found (309.0803). 
7-Fluoro-9-(4-fluorobenzyl)furo[2,3-b]quinoline-3,4 (2H,9H)-dione (lSb) : 
The title compound was synthesized according to the procedure used for compound 15a except that the 
fluorobenzyl chloride was used to yield compound 15b as an amorphous powder (0.579 g, 9.7%). Mp: > 
200 °C. 1a NMR (CDCb, 300 MHz) 8 : 8.42 (s, 1H), 7.00-7.25 (m, 6H), 5.42 (s, 2H), 4.81 (s, 2H). 
APCI-MS (+ve mode): (mls) 328.2 ([M+H} +, 100); HR-MS (Ef} (m/z) calcd for C18H 11F2N03 
(327.2816); found (327.0719). 
7-Fluoro-9-(4-methoxybenzyl)furo[2,3-b]quinoline-3,4 (2H,9H)-dione (15c): 
The title compound was synthesized according to the procedure for compound 15a except that the p-
methoxybenzyl chloride was used here to yield compound 15c as an amorphous powder (0.618 g, 10%). 
Mp: > 200 °C. 1a NMR (CDCh, 300 MHz) 8: 8.47 (dd, J = 9.1 Hz, J= 6.4 Hz, 1H), 7.20-7.03 (m, 4H), 
6.92 (d, J= 8.7 Hz, 2H), 5.38 (s, 2H), 4.82 (s, 2H), 3.79 (s, 3H). APCI-MS (+ve mode): m/z 339.3 
[M+Ht, 1 00). 
7-Fluoro-9-cyanomethylfuro[2,3-b]quinoline-3,4 (2H,9H)-dione (15d): 
The title compound was synthesized according to the procedure used to synthesize compound 15a except 
that the bromoacetonitri1e was used here to yield compound 15d as amorphous powder (0.387 g, 8%). 
Mp: > 200 °C. 1a NMR (CDCb, 300 MHz) 8: 8.32-8.24 (m, 1H), 7.93-7.84 (m, 1H), 7.45-7.35 (m, 1H), 
5.63 (s, 2H), 5.00 (s, 2H). APCI-MS (+ve mode): mlz 259.2 [M+Ht, 100), HR-MS (Ef} calcd for 
C1sH12FN20 3 (258.2046); found (258.0447). 
3-Chloro-7-fluoro-4-oxo-4,9-dihydrofuro[2,3-b]quinoline-2-carbaldehyde (16): 
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To a cold solution of phosphorus oxychloride (13 .98 g, 91.2 mmol) in DMF (10 mL) , compound 14 (4.00 
g, 18.25 mmol) was added. The mixture was stirred at 50-60 °C for 5-6 h, cooled to room temperature 
then poured into ice-cold water. The residue was extracted with DCM (15 mL) and the organic layer was 
dried over sodium sulfate and evaporated under vacuum to give a dark brown residue which was then 
precipitated using DCM/hexane to give compound 16 as a dark yellow amorphous powder (0.531 g, 
11%). Mp = 190-195. 1H NMR (CDCI3, 300 MHz) 8: 10.07 (s, 1H), 8.48-8.43 (dd, J= 9.4 Hz, J= 6.1 
Hz, 1H), 7.95-7.90 (dd, J= 10.1 Hz, J= 2.5 Hz, 1H), 7.79-7.72 (m, 1H). APCI-MS (- ve mode): (mlz) 
264.1 ([M-Ht, 1 00). 
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CHAPTER4 
Conclusion and Future Research 
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One of the most successful achievements in the development of antibacterial agents was the 
synthesis of fluoroquinolones. Since then quinolones have been widely used clinically as antibacterial 
agents. They are the most popular antibiotics possesing broad spectrum of activity in humans. Quinolones 
have a very unique mode of action in that they act against two prokaryotic enzymes, DNA gyrase and 
topoisomerase IV, in a similar fashion. These agents target the topoisomerase catalytic cycle when the 
enzyme is covalently linked to the stabilized cleavage complex, thus blocking the progression of the 
replication and creating lesions. The structural distortion of the double helix stabilized by specific contact 
with the enzyme residues provides a favorable interaction site for quinolones. The common features in 
the mechanism of action of antibacterial quinolones and antitumor drugs of the epipodophyllotoxin family 
have provided a new light in this area of research thus directing quinolones to be used as potential 
anticancer agents. 
As outlined in the Chapter 3 of this dissertation, we focused on the syntheses and testing of 
various derivatives of quinolones such as N-alkylated-, 0-alkylated-thienoquinolones and furoquinolones, 
and attempted to study the cytotoxic profile of these compounds . All of the compounds have been 
synthesized by adaptation of the reported procedures in the references. The starting point of this research 
was set up by a graduate student, Zohreh Amoozgar, under the supervision of Dr. Mohsen Daneshtalab. 
An interesting chemistry has been studied on the behaviour of selectivity of alkylation using modified 
Mitsunobu reaction and base-catalyzed alkylation methods. In this study, as outlined in Chapter 3, we 
found that the Mitsunobu reaction is more oriented towards 0-alkylation whereas parallel studies 
performed on the regioselectivity of alkylation in quinolones using base-catalyzed alkylation method gave 
a mixture of both 0-alkylated and N-alkylated quinolones. The results of attempted alkylation reactions 
proved that the Mitsunobu method gives regioselectively 0-alkylated quinolone analogues while the 
traditional base-catalyzed alkylations afford both N- and 0-alkylated derivatives. In order to confirm the 
above assignment, we synthesized the N-alkylated quinolones by a different synthetic method. In the 
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same context, we reassigned the chemical shifts of the methylene protons attached to 0-alkylated and N-
alkylated products and proved the wrong assignments of these chemical shifts in previously published 
papers. Upon cytotoxicity testing of the synthesized compounds on both HeLa and Kb cell lines, we 
observed that despite weak cytotoxic activity of the majority of the synthesized compounds, a few of 
them have reasonable cytotoxicity against the above cell lines. Thus, we believe, with appropriate 
modifications of these compounds we can enhance the cytotoxic profile ofthe so called thienoquinolones 
and furoquinolones. 
Based on this research and upon analyzing the results of biological assessments of the compounds 
synthesized, I would like to further dwell into this area by doing structural modification of the test 
compounds and explore their chemistry and biological activity profiles. (Figure 4.1) 
~HR, 
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Figure 4.1. Proposed structures of future compounds to be synthesized 
Based on the observations in the current project on the synthesis of various carboxylic acid 
analogues, I predict the suggested modifications may improve the cytotoxic profile of this class of 
90 
Chapter 3: Design, Synthesis & Biological Evaluation ofQuinolone-[2,3-b]thienoquinolones and Furoquinolones 
compounds due to improvement in the metal-ion chelating characteristics of the proposed molecules and 
further strengthening of bonding with the target protein molecule, topoisomerase II. 
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